Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes

NCT02641522 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: Siltuximab

Sponsor

Carla Greenbaum, MD

Collaborators

[object Object]